Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

View through bone © Shutterstock

During ageing, cellular and physiological processes naturally decline and this is a particular problem in collagen-rich tissues such as the articular cartilage and bone, where tissue turnover is low and repair of the tissue is reduced with age. Reduced repair capacity increases the risk of common age-related diseases such as osteoarthritis (OA), non-union after bone fracture, and osteoporosis.

Protein studies have previously indicated levels of protein in a tissue at any given time, but are unable to provide information on how much is being newly synthesised and incorporated into the tissue. A new study, published in ELife,  uses a new methodology that gives researchers the ability to examine protein synthesis in situ, providing details of activity in the tissues under normal physiological conditions at different ages.

The tissues in the cartilage, bone and skin are made up of an extracellular matrix (ECM), which is a dynamic network composed of collagens and proteins, and collectively known as the matrisome.

The research team at the Kennedy Institute used an in vivo technique called pulsed SILAC labelling in healthy mice to show changes in the synthesis of proteins of the matrisome over three stages of life: during maximum skeletal growth, and at young, and older adulthood.

Metabolic labelling with stable isotopes in combination with quantitative proteomics were used to estimate the rates of incorporation of new proteins into cartilage, bone and skin. Plasma was used as a reference tissue comparator.

The study found that comparing young adult with older adult mice, new protein incorporation was reduced in all tissues and this was particularly marked in cartilage and bone. Changes were less apparent in skin, perhaps in line with what is known about its ability to self-renew throughout the healthy lifespan.

Tonia Vincent, Professor of Musculoskeletal Biology said: "Although new protein incorporation changes significantly in all tissues after skeletal maturity, it displays distinct temporal and molecular tissue signatures. As some of these changes affect pathways implicated in age-related disease, the study may be identifying tissue changes that predispose to subsequent osteoarthritis and osteoporosis."

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.